Literature DB >> 7923119

Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.

D L Earnest1, H Holubec, R K Wali, C S Jolley, M Bissonette, A K Bhattacharyya, H Roy, S Khare, T A Brasitus.   

Abstract

The present studies were conducted at the Universities of Chicago and Arizona to examine and compare the effects of supplemental dietary ursodeoxycholic acid to cholic acid, a known tumor promoter, and to piroxicam, a known chemopreventive agent, in the azoxymethane (AOM) model of experimental colonic carcinogenesis. Male Fischer 344 rats were utilized in these experiments. All animals were fed a basal diet (AIN-76) supplemented with 0.2% or 0.4% cholic acid, 0.2% or 0.4% ursodeoxycholic acid, 0.2% ursodeoxycholic acid plus 0.2% cholic acid, or 75 ppm piroxicam. Rats were given s.c. injections once a week for 2 weeks with AOM (15 mg/kg body wt/week) or vehicle (saline) after being fed their respective diets for 2 weeks. The rats in each group were then maintained on their respective diets for approximately 28 weeks; after sacrifice, their colons were removed and examined macroscopically and microscopically for the presence of tumors. The results of these studies demonstrated that none of the control rats fed the various diets injected with AOM-vehicle developed tumors. In groups receiving AOM, the addition of cholic acid (0.4%) caused a significant increase in the incidence of tumors. In contrast, the addition of 0.2% ursodeoxycholic acid did not promote AOM-induced colonic tumors, and when it was added to a promoting dose of cholic acid (0.2%), 0.2% ursodeoxycholic acid prevented enhancement of tumor promotion. At higher doses (0.4%), supplemental dietary ursodeoxycholic acid significantly reduced the incidence of colon tumors and cancers. Moreover, the tumor suppressive effects of 0.4% ursodeoxycholic acid exceeded that of dietary piroxicam. Our results further emphasize the important role of bile salts in modulating colonic tumor development. These studies also demonstrate for the first time that supplemental dietary ursodeoxycholic acid is a chemopreventive agent in the AOM model of experimental colonic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923119

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

Review 2.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

3.  Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line.

Authors:  Kunrong Cheng; Guofeng Xie; Jean-Pierre Raufman
Journal:  Biochem Pharmacol       Date:  2006-12-10       Impact factor: 5.858

Review 4.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 5.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

6.  Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.

Authors:  Urszula Dougherty; Dario Cerasi; Ieva Taylor; Masha Kocherginsky; Ummuhan Tekin; Shamiram Badal; Lata Aluri; Amikar Sehdev; Sonia Cerda; Reba Mustafi; Jorge Delgado; Loren Joseph; Hongyan Zhu; John Hart; David Threadgill; Alessandro Fichera; Marc Bissonnette
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

7.  Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Authors:  Patricia A Thompson; Betsy C Wertheim; Denise J Roe; Erin L Ashbeck; Elizabeth T Jacobs; Peter Lance; María Elena Martínez; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

8.  Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR.

Authors:  Rebecca Feldman; Jesse D Martinez
Journal:  Biochim Biophys Acta       Date:  2009-05-13

Review 9.  Colorectal polyps in the elderly: what should be done?

Authors:  Kenneth Miller; Jerome D Waye
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation.

Authors:  I Soo; K L Madsen; Q Tejpar; B C Sydora; R Sherbaniuk; B Cinque; L Di Marzio; M Grazia Cifone; C Desimone; R N Fedorak
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.